Top

Current Hematologic Malignancy Reports

Published in:

01-06-2019 | Nutrition | Myeloproliferative Neoplasms (B Stein, Section Editor)

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions

Authors: Prathibha Surapaneni, Robyn M. Scherber

Published in: Current Hematologic Malignancy Reports | Issue 3/2019

Abstract

Purpose of Review

Myeloproliferative neoplasms (MPNs) have a high symptom burden that affects functional status, emotional well-being, and quality of life for patients. Symptom control continues to be a challenging therapeutic goal despite available pharmacologic interventions. The goal of this review is to detail recent efforts that have focused on non-pharmacologic interventions, such as wholistic or integrative medicine, as an adjunctive method to alter symptom burden in this population.

Recent Findings

We discuss the ongoing physical, nutritional, and psychological interventional efforts which represent promising non-traditional interventions to date to help reduce symptom in MPN patients. In this article, we highlight the early promising data and importance of these various non-pharmacological interventions to dampen symptom burden and reduce disease-related inflammation.

Summary

Nonpharmacologic interventions represent promising therapeutic strategies to alter traditional MPN treatment paradigms and improve MPN patient care.

O'Sullivan J and Mead AJ. Heterogeneity in myeloproliferative neoplasms: causes and consequences. Adv Biol Regul. 2018. https://doi.org/10.1016/j.jbior.2018.11.007.

2.••

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85 Details the multifactorial nature of symptom burden in MPN populations and details the early findings of patient-directed integrative treatments to impact symptom burden and fatigue.CrossRefPubMed

3.••

Geyer HL, et al. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediat Inflamm. 2015;2015:284706 This study summarizes the data that demonstrates the link between MPN symptoms to disease-related inflammation.CrossRef

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRefPubMedPubMedCentral

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. BLood. 2011;118(2):401–8.CrossRefPubMed

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefPubMed

Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56(7):1989–99.CrossRefPubMed

Geyer H, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. 2015;126(23):4080–4080.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96(10):1653–65.CrossRefPubMedPubMedCentral

10.

Geyer, HL and R.A. Mesa, Therapy for myeloproliferative neoplasms: when, which agent, and how?. 2014;124:(24): p. 3529–3537.

11.

Huberty J, et al. Online-streamed yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms. 2016;128(22):5478–5478.

12.

Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implication of inadequately controlled disease. 2016;34(2):151–159. https://doi.org/10.1200/jco.201562.9337.

13.

Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. 2016;34(2):151–159.

14.

Craver BM, et al. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers (Basel) 2018;10(4). https://doi.org/10.3390/cancer10040104.

15.

Scherber R, et al. The relationship of BMI to symptom burden in the myeloproliferative neoplasms. Haematologia. 2017;102(S2):215667.

16.

Marty C, Lacout C, Droin N, le Couédic JP, Ribrag V, Solary E, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187–95.CrossRefPubMed

17.

McFarland DC, Shaffer KM, Polizzi H, Mascarenhas J, Kremyanskaya M, Holland J, et al. Associations of physical and psychologic symptom burden in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Psychosomatics. 2018;59(5):472–80.CrossRefPubMedPubMedCentral

18.••

Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2019;11:23–33 Demonstrates the importance of cognitive and emotional issues in MPN patients.CrossRefPubMed

19.

Eckert R, et al. A pilot study of online yoga to improve fatigue and quality of life in myeloproliferative neoplasm patients. 2017;130(Suppl 1):3443–3.

20.

Simister HD, Tkachuk GA, Shay BL, Vincent N, Pear JJ, Skrabek RQ. Randomized controlled trial of online acceptance and commitment therapy for fibromyalgia. J Pain. 2018;19(7):741–53.CrossRefPubMed

21.

Jacobsen HB, Kallestad H, Landrø NI, Borchgrevink PC, Stiles TC. Processes in acceptance and commitment therapy and the rehabilitation of chronic fatigue. Scand J Psychol. 2017;58(3):211–20.CrossRefPubMed

22.

Vowles KE, et al. An analysis of within-treatment change trajectories in valued activity in relation to treatment outcomes following interdisciplinary acceptance and commitment therapy for adults with chronic pain. Behav Res Ther. 2019;115:46–54. https://doi.org/10.1016/j.brat.2018.10.012.

23.

Kangas M, McDonald S, Williams JR, Smee RI. Acceptance and commitment therapy program for distressed adults with a primary brain tumor: a case series study. Support Care Cancer. 2015;23(10):2855–9.CrossRefPubMed

24.

Mosher CE, Secinti E, Li R, Hirsh AT, Bricker J, Miller KD, et al. Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. Support Care Cancer. 2018;26(6):1993–2004. https://doi.org/10.1007/s00520-018-4045-0.

25.

Padrnos L, Kosiorek H, Scherber R, Knight E, Cuc A, Stonnington C, Dueck A, Geda Y, Mesa R. Myeloproliferative neoplasms and acceptance and commitment therapy: an ongoing feasibility study aimed at symptom mitigation and quality of life. EHA, 2018;(216851).

26.

Van Dam NT, et al. Mind the hype: a critical evaluation and prescriptive agenda for research on mindfulness and meditation. Perspect Psychol Sci. 2018;13(1):36–61.CrossRefPubMed

27.

Mesa RA, et al. Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the Pre JAK2 inhibitor era 2009;114(22):3918–3918.

28.

Mitrou PN, Kipnis V, Thiébaut AC, Reedy J, Subar AF, Wirfält E, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2007;167(22):2461–8.CrossRefPubMed

29.

Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA Study. J Am Coll Cardiol. 2004;44(1):152–158. https://doi.org/10.1016/j.jacc.2004.03.039.

30.

Smidowicz A, Regula J. Effect of nutritional status and dietary patterns on human serum C-reactive protein and interleukin-6 concentrations. Adv Nutr. 2015;6(6):738–47.CrossRefPubMedPubMedCentral

31.

Kuriakose E. The JAK2V617F mutation seen in myeloproliferative neoplasms (MPNs) occurs in patients with inflammatory bowel disease: implications of a pilot study. Int J Clin Med. 2013;4:10–5.CrossRef

32.

Scherber R, et al. Nutritional needs and preferences of myeloproliferative neoplasm patients: Phase I A of the NUTRIENT Study. EHA Abstract pending acceptance, 2017.

33.

Scherber R, et al. Needs and preferences regarding nutrition and supplement use among individuals with myeloproliferative neoplasms. Proceedings of the 9th international congress on myeloproliferative neoplasms. 2017.

Title: Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions
Authors: Prathibha Surapaneni
Robyn M. Scherber
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Nutrition
Fatigue
Published in: Current Hematologic Malignancy Reports / Issue 3/2019
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-019-00516-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2019

Disparities in Survival and Health Outcomes in Childhood Leukemia

Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms

Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment

Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page